Recombinant Anti-Human EGFR VHH Single Domain Antibody (9G8)

Figure 1 In vitro characterisation of selected monovalent anti‐EGFR sdAbs.

The binding of biotinylated EGF (800 pM) to an EGFR‐ECD‐Fc fusion was tested in the presence of increasing amounts of the 9G8, 7D12, 7C12 or 38G7 sdAbs, or without sdAb. Receptor‐bound EGF was then detected via peroxidase‐coupled streptavidin and staining with OPD/H2O2.

Roovers, R. C., Vosjan, M. J., Laeremans, T., el Khoulati, R., de Bruin, R. C., Ferguson, K. M., ... & van Bergen en Henegouwen, P. M. (2011). A biparatopic anti‐EGFR sdAb efficiently inhibits solid tumour growth. International journal of cancer, 129(8), 2013-2024.

Figure 2 In vitro characterisation of selected monovalent anti-EGFR sdAbs.

The binding of the 9G8 sdAbs to EGFR, expressed on phage, was detected in a 100‐fold molar excess of the indicated antibody (cetuximab) or antibody fragments.

Roovers, R. C., Vosjan, M. J., Laeremans, T., el Khoulati, R., de Bruin, R. C., Ferguson, K. M., ... & van Bergen en Henegouwen, P. M. (2011). A biparatopic anti‐EGFR sdAb efficiently inhibits solid tumour growth. International journal of cancer, 129(8), 2013-2024.

Figure 3 Inhibition of A431 tumour cell proliferation by monovalent and bivalent sdAbs.

The proliferation of A431 cells in the presence of increasing amounts of sdAb monovalent and bivalent 9G8

Roovers, R. C., Vosjan, M. J., Laeremans, T., el Khoulati, R., de Bruin, R. C., Ferguson, K. M., ... & van Bergen en Henegouwen, P. M. (2011). A biparatopic anti‐EGFR sdAb efficiently inhibits solid tumour growth. International journal of cancer, 129(8), 2013-2024.

Figure 4 Purity and specificity of sdAb–PS conjugates.

Fluorescence intensities of cell bound conjugates are plotted after incubation of OSC cells with varying concentrations of the EGFR targeted conjugates 7D12–PS and 7D12-9G8–PS, or the controls R2–PS and PS.